Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Azidothymidine (HB4602)
Description:Selective reverse transcriptase inhibitor with anti-HIV activity. Decreases CRISPR-mediated homology directed repair (HDR) and enhances gene knockout efficiency.
Purity:>98%
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
- Description:
Selective α-mannosidase I inhibitor
Hypericin (HB3934)
Description:Photosensitive compound. Shows anticancer, antiviral and antidepressant action.